Zentalis Pharma Files Routine 8-K, Updates Admin Info
Ticker: ZNTL · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1725160
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, 8-K
TL;DR
**Zentalis Pharma filed a standard 8-K, no major news.**
AI Summary
Zentalis Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 5, 2024. This filing is a routine current report, primarily updating administrative details such as their business address at 1359 Broadway, Suite 801, New York, New York 10018. For investors, this filing indicates no significant operational or financial changes, suggesting business as usual for the company.
Why It Matters
This filing is largely administrative and does not contain new material financial or operational information, meaning it has minimal immediate impact on Zentalis Pharmaceuticals' stock valuation.
Risk Assessment
Risk Level: low — The filing is administrative and does not disclose any new risks or significant changes to the company's operations or financial health.
Analyst Insight
Investors should note this is a standard administrative filing and does not contain new information that would typically warrant a change in investment strategy. It's important to monitor for subsequent filings that might contain more substantive news.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- January 5, 2024 (date) — date of earliest event reported
- January 8, 2024 (date) — date the 8-K was filed
- 1359 Broadway, Suite 801, New York, New York 10018 (address) — principal executive offices of Zentalis Pharmaceuticals, Inc.
- (212) 433-3791 (phone_number) — registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Zentalis Pharmaceuticals, Inc.?
This 8-K filing is a 'Current Report' pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily for 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits', though the provided text only details administrative information and the filing structure.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 5, 2024.
What is the business address listed for Zentalis Pharmaceuticals, Inc. in this filing?
The business address for Zentalis Pharmaceuticals, Inc. is 1359 Broadway, Suite 801, New York, New York 10018.
What is the Commission File Number for Zentalis Pharmaceuticals, Inc.?
The Commission File Number for Zentalis Pharmaceuticals, Inc. is 001-39263.
Has Zentalis Pharmaceuticals, Inc. changed its name recently, according to the filing's historical data?
Yes, the filing indicates Zentalis Pharmaceuticals, Inc. was formerly known as Zentalis Pharmaceuticals, LLC (changed on 20200107) and before that, Zeno Pharma, LLC (changed on 20171212).
Filing Stats: 616 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-01-08 07:03:29
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
- $35 million — lis will receive an up-front payment of $35 million in cash and Immunome common stock. Zent
- $275 million — talis will be eligible to receive up to $275 million of milestone payments for ZPC-21 and ot
Filing Documents
- zntl-20240105.htm (8-K) — 35KB
- immunome-projectlionpressr.htm (EX-99.1) — 21KB
- image_0.jpg (GRAPHIC) — 13KB
- image_1.jpg (GRAPHIC) — 11KB
- 0001725160-24-000007.txt ( ) — 223KB
- zntl-20240105.xsd (EX-101.SCH) — 2KB
- zntl-20240105_lab.xml (EX-101.LAB) — 24KB
- zntl-20240105_pre.xml (EX-101.PRE) — 13KB
- zntl-20240105_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 8, 2024, Zentalis Pharmaceuticals, Inc. ("Zentalis") issued the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and incorporated herein by reference. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. Immunome Exclusively Licenses Zentalis ROR1 ADC and Underlying Technology Platform to Immunome On January 5, 2024, Zentalis entered into an exclusive, worldwide license agreement with Immunome, Inc. ("Immunome"), under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug conjugate ("ADC") with best-in-class potential, and Zentalis' proprietary ADC platform technology. Under the terms of the deal, Zentalis will receive an up-front payment of $35 million in cash and Immunome common stock. Zentalis will be eligible to receive up to $275 million of milestone payments for ZPC-21 and other products that utilize the licensed platform technology in addition to mid-to-high single-digit royalties.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits ExhibitNo. Description 99.1 Press Release issued on January 8, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: January 8, 2024 By: /s/ Melissa Epperly Melissa Epperly Chief Financial Officer